Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
Total Valuation
Supernus Pharmaceuticals has a market cap or net worth of $1.77B. The enterprise value is $1.62B.
Market Cap$1.77B
Enterprise Value$1.62B
Share Statistics
Supernus Pharmaceuticals has 55.81M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55.81M
Owned by Insiders4.12%
Owned by Instutions28.93%
Financial Efficiency
Supernus Pharmaceuticals’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 5.69%.
Return on Equity (ROE)7.13%
Return on Assets (ROA)5.40%
Return on Invested Capital (ROIC)5.69%
Return on Capital Employed (ROCE)7.59%
Revenue Per Employee$981,924.332
Profits Per Employee$109,591.988
Employee Count674
Asset Turnover0.48
Inventory Turnover1.43
Valuation Ratios
The current PE Ratio of Supernus Pharmaceuticals is 26.97. Supernus Pharmaceuticals’s PEG ratio is <0.01.
PE Ratio26.97
PS Ratio3.01
PB Ratio1.92
Price to Fair Value1.92
Price to FCF11.64
Price to Operating Cash Flow11.59
PEG Ratio<0.01
Income Statement
In the last 12 months, Supernus Pharmaceuticals had revenue of $661.82M and earned $73.86M in profits. Earnings per share was $1.34.
Revenue$661.82M
Gross Profit$522.37M
Operating Income$76.22M
Pretax Income$97.87M
Net Income$73.86M
EBITDA165.68M
Earnings Per Share (EPS)1.34
Cash Flow
In the last 12 months, operating cash flow was $171.95M and capital expenditures -$725.00K, giving a free cash flow of $171.23M billion.
Operating Cash Flow$171.95M
Free Cash Flow$171.23M
Free Cash Flow per Share$3.07
Dividends & Yields
Supernus Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield8.59%
Earnings Yield3.71%
Stock Price Statistics
Beta0.50
52-Week Price Change5.37%
50-Day Moving Average33.67
200-Day Moving Average33.75
Relative Strength Index (RSI)44.94
Average Volume (3m)706.40K
Important Dates
Supernus Pharmaceuticals upcoming earnings date is May 13, 2025, After Close.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Supernus Pharmaceuticals as a current ratio of 2.35, with Debt / Equity ratio of 0.03
Current Ratio2.35
Quick Ratio2.16
Debt to Market Cap0.01
Net Debt to EBITDA-0.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Supernus Pharmaceuticals has paid $24.00M in taxes.
Income Tax$24.00M
Effective Tax Rate24.53%
Enterprise Valuation
Supernus Pharmaceuticals EV to EBITDA ratio is 10.98, with an EV/FCF ratio of 11.43.
EV to Sales2.96
EV to EBITDA10.98
EV to Free Cash Flow11.43
EV to Operating Cash Flow11.38
Balance Sheet
Supernus Pharmaceuticals has $453.61M in cash and marketable securities with $34.27M in debt, giving a net cash position of -$419.34M billion.
Cash & Marketable Securities$453.61M
Total Debt$34.27M
Net Cash-$419.34M
Net Cash Per Share-$7.51
Tangible Book Value Per Share$7.20
Margins
Gross margin is 88.23%, with operating margin of 12.34%, and net profit margin of 11.16%.
Gross Margin88.23%
Operating Margin12.34%
Pretax Margin14.79%
Net Profit Margin11.16%
EBITDA Margin26.94%
EBIT Margin14.79%
Analyst Forecast
The average price target for Supernus Pharmaceuticals is $38.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$38.80
Price Target Upside22.78%
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast8.94%
EPS Growth Forecast5171.26%